

RESEARCH

Open Access



The influence of pyroptosis-related genes on the development of chronic obstructive pulmonary disease

Xinlong Liu¹, Xiaoling Huang^{1*} and Feng Xu^{1*}

Abstract

Increasing evidences have demonstrated that pyroptosis exerts key roles in the occurrence, development of chronic obstructive pulmonary disease. However, the mechanisms of pyroptosis in COPD remain largely unknown. In our research, Statistics were performed using R software and related packages in this study. Series matrix files of small airway epithelium samples were downloaded from the GEO database. Differential expression analysis with FDR < 0.05 was performed to identify COPD-associated pyroptosis-related genes. 8 up-regulated genes (CASP4, CASP5, CHMP7, GZMB, IL1B, AIM2, CASP6, GSDMC) and 1 down-regulated genes (PLCG1) was identified as COPD-associated pyroptosis-related genes. Twenty-six COPD key genes was identified by WGCNA analysis. PPI analysis and gene correlation analysis showed their relationship clearly. KEGG and GO analysis have revealed the main pyroptosis-related mechanism of COPD. The expression of 9 COPD-associated pyroptosis-related genes in different grades was also depicted. The immune environment of COPD was also explored. Furthermore, the relationship of pyroptosis-related genes and the expression of immune cells was also be shown in the end. In the end, we concluded that pyroptosis influences the development of COPD. This study may provide new insight into the novel therapeutic targets for COPD clinical treatment.

Keywords Chronic obstructive pulmonary disease, Pyroptosis-related genes, Occurrence, Development, Immune environment

Introduction

Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease characterized by persistent respiratory symptoms, progressive airflow limitation. Because of the lack of effective treatment, this disease leads to high mortality [1]. Despite significant progress in the treatment and prevention of

acute exacerbations, the advances in ameliorating disease progression and mortality are limit. Thus, a greater understanding of the mechanisms resulting in COPD is urgently needed [2]. At present, some evidences reported that pyroptosis has been considered to be involved in the occurrence and development of COPD [3]. Inhibition of pyroptosis in respiratory system could reduce the injury of lung cells, the production of inflammatory factors and inflammatory response [4].

Pyroptosis, an inflammatory programmed cell death pathway, is considered as a non-specific defense mechanism of the body [5]. The activation of pyroptosis mainly involves two pathways [6]. It is currently recognized that the classical pathway is the activation of the inflammatory Caspase-1, which promotes the cleavage of

*Correspondence:

Xiaoling Huang
hxxling@163.com
Feng Xu
xufengprivate@163.com

¹ Department of Intensive Care Unit, University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen, Guangdong, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

gasdermin D (GSDMD) and the release of IL-1 β and IL-18 [7, 8]. The noncanonical pathway is the activation of the caspase-4/5 regulated by cytosolic bacterial lipopolysaccharide (LPS) [9]. Currently, known inflammasomes include the NLRP1, NLRP3, NLRC4, AIM2, and the PYRIN inflammasome, which have been studied intensively. Following prior researches, numerous factors activate the inflammasomes, including exogenous and endogenous danger signals [7]. Inflammasomes are involved in host immune defense, but excessive inflammatory damage and pyroptosis will lead to irreversible injuries. As reported, inflammasomes are involved in both COPD stable and exacerbations [10]. Inhalation of harmful particles and gases activate the pattern recognition receptors in the lungs, then trigger downstream signaling pathways of the nuclear factor (NF)- κ B, which lead to airway inflammation in COPD [11]. Caspase-1, a cysteine protease, is located downstream of inflammatory pathway to activate Gasdermin-D [12]. The N-terminal domains of cleaved Gasdermin-D lead to a loss of membrane integrity, which induce pyroptosis eventually [13]. Furthermore, activated inflammasomes like NLRP3, NLRC4 and AIM2 also influence trigger the activation of caspase-1, which cleaves the cytokine precursors interleukin-1B (pro-IL-1B) and interleukin-18 (pro-IL-18) to active pro-inflammatory factors IL-1B and IL-18 [14].

The aim of this study was to identify key genes in COPD and to investigate the relationship between COPD key genes and pyroptosis-related genes by integrating bioinformatics tools. Also, the correlation between pyroptosis-related genes and immune infiltration have been explored. This study also provides new insight into the novel therapeutic targets for COPD clinical treatment.

Materials and methods

Information of COPD patients

The datasets of our research were downloaded from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). The retrieval condition is set with the subject word of "chronic obstructive pulmonary disease", the research type of "expression profiling by array", and the species of "homo sapiens". Series matrix files of small airway epithelium samples obtained by fiberoptic bronchoscopy including GSE5058, GSE8545, GSE11906, GSE20257 and GSE69818 were selected. To eliminate batch effects, R package "sva" and "limma" were applied for batch effect normalization [15]. Therefore, the train set consisted of GSE8545 and GSE20257, which contained 95 healthy controls and 27 COPD patients. The test set was comprised by GSE5058

and GSE11906 including 81 healthy controls and 45 COPD cases. GSE69818 consisted of 70 former smokers with COPD including 9 cases with The Global Average of COPD (GOLD) stage 1, 41 cases with GOLD stage 2, 9 cases with GOLD stage 3, and 9 cases with GOLD stage 4.

PPI analysis and gene correlation analysis

We performed protein–protein interaction (PPI) analysis by the STRING database (<http://www.string-db.org/>). The R package "limma" and "corrplot" was applied to perform differential expression analysis. The expression of 9 COPD-associated pyroptosis-related genes in different GOLD states was revealed using GSE69818, which completed by R packages "limma", "ggplot2" and "ggpubr" [16].

Identification of COPD-associated pyroptosis-related genes

According to the previous researches for pyroptosis [17–21], the expression matrixes of 47 pyroptosis-related genes were extracted. Differential expression analysis for 47 pyroptosis-related genes between COPD patients and health cases was conducted by wilcoxtest [22].

Identification of COPD key genes

Using the "limma" package, the differentially expressed genes (DEGs) between COPD patients and health controls for the train set and test set were respectively identified. DEGs were filtered by $|\log_2 \text{fold change (FC)}| > 1$ and $\text{adjust } P \text{ value} < 0.05$. The overlapped DEGs were acquired [23].

The DEGs ($\text{FDR} < 0.05$) obtained from test set were used to identify the hub COPD genes by weighted correlation network analysis (WGCNA) on mRNA expression data of train set [23]. The adjacency matrix was transformed into the topological overlap matrix (TOM) when the power was equal to 8 ($R^2 = 0.9$) [24]. Filtered by the $\text{cor. COPD} > 0.2$ and the $\text{cor. module membership} > 0.6$, the hub genes were obtained. The intersectant genes of the overlapped DEGs and hub COPD genes were defined as key COPD genes.

KEGG and GO enrichment analyses

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and Gene Ontology (GO) functional analyses were conducted to analyze 9 COPD-associated pyroptosis-related genes and 26 COPD key genes by R packages "colorspace", "stringi" and "ggplot2". The $P \text{ value} < 0.05$ and $q \text{ value} < 0.05$ were set as the cutoff criterion [25–27].

Evaluation of tissue-infiltrating immune cells

The R package “CIBERSORT.R” was used to estimate the relative proportions of 22 types of immune cells [28]. CIBERSORT, a kind of deconvolution algorithm, transform the normalized gene expression matrix into the corresponding infiltrating immune cell expression matrix, which provide a reliable composition of infiltrating immune cells. The results were visualized using the R packages “corrplot”, “vioplot”, “ggplot2”, and “dplyr” [29].

Result

Expression of pyroptosis-related genes in COPD

Forty-seven pyroptosis-related genes have showed in Supplemental Table 1. We performed PPI analysis to further understand biological interactions among 47 pyroptosis-related genes (Fig. 1A). Figure 1B showed that these pyroptosis-related genes presented highly significant correlations. Furthermore, we investigated the expression correlation among these pyroptosis-related




Fig. 1 PPI analysis and gene correlation analysis for 47 pyroptosis-related genes. **A** The protein–protein interactions among 47 pyroptosis-related genes. **B** The rank of connection degree (number) for each gene. **C** Correlation among the expression of 47 pyroptosis-related genes in the train set. P values are shown as: * $p < 0.05$. **D** Correlation among the expression of 47 pyroptosis-related genes in the test set. P values are shown as: * $p < 0.05$




Fig. 2 Expression of pyroptosis-related genes in COPD. **A-B** Heatmap and boxplot of expression levels of 47 pyroptosis-related genes in train set. *P*-values are shown as: **p* < 0.05; ***p* < 0.01; ****p* < 0.001; **(C-D)** Heatmap and boxplot of expression levels of 47 pyroptosis-related genes from test set. *P*-values are shown as: **p* < 0.05; ***p* < 0.01; ****p* < 0.001

genes. The result we obtained showed that a basically consistent correlation among 47 pyroptosis-related gene in both train set and test set (Fig. 1C, D).

The clinical information of samples have revealed in Supplemental Table 2. The differential expression analysis for 47 pyroptosis-related gene between the COPD patients and healthy cases was conducted in the train set (Fig. 2A-B) and test set (Fig. 2C-D). Therefore, these results indicated that the expression of pyroptosis-related

gene may influence the occurrence of COPD. Based on the $FDR < 0.05$, we found that 9 pyroptosis-related genes were related to the occurrence of COPD significantly, with 8 up-regulated (CASP4, CASP5, CHMP7, GZMB, IL1B, AIM2, CASP6, GSDMC) and 1 down-regulated genes (PLCG1) in COPD patients in both train set and test set (Supplemental Table 3). And we then also named these 9 pyroptosis-related genes as COPD-associated pyroptosis-related genes.




Fig. 3 Identification of Key genes. **A** Clustering dendrograms of genes based on a dissimilarity measure (1-TOM). **B** Analysis of the scale-free fit index (left) and the mean connectivity (right) for various soft-thresholding powers. **C** Module-trait associations were evaluated by correlations between module eigengenes and sample traits. **D-F** Scatterplot of Gene Significance for COPD in black, brown, grey, yellow module

Identification of DEGs in COPD

Filtered by $|\log FC| > 1$ and $FDR < 0.05$, 89 DEGs including 17 down-regulated and 72 up-regulated genes were acquired from the train set. Similarly, 86 DEGs including 36 down-regulated and 50 up-regulated genes were acquired from the test set. Finally, we got 38 overlapped DEGs.

Identification of the key genes

To identify the modules associated with the occurrence of COPD, we conducted WGCNA with the train set for 4308 genes acquired from test set filtered by $FDR < 0.05$. A soft-thresholding power of 8, for which

the scale-free topology fit index reaches 0.90 (Fig. 3B), which was applied to establish a hierarchical clustering tree (Fig. 3A).

We analyzed the module trait relationship to further investigate the modules associated with COPD. Subsequently, eight modules were identified (Fig. 3C). The correlation between ME and traits shows that some modules are more important than others in the COPD. On the basis of $cor. COPD > 0.2$ and $cor. module membership > 0.6$, 213 hub COPD genes with the high connectivity in black, brown, green and yellow modules (Fig. 3D-G) were selected out. By taking the intersection of 38 overlapped DEGs and 213 hub COPD genes. Finally, 26 COPD key genes were acquired (Table 1).

Table 1 Twenty-six COPD key genes positively or negatively associated with COPD and each MM

Key gene	Module color	Cor.MM	Cor.COPD	Up or down
TCN1	Black	0.81000672	0.51908694	Up
CEACAM5	Black	0.89938687	0.485623553	Up
AHRR	Brown	0.76642944	0.478708318	Up
CYP1B1	Brown	0.91138241	0.452711387	Up
CYP1A1	Brown	0.72255337	0.426468786	Up
SLC7A11	Brown	0.9216228	0.390531602	Up
CABYR	Brown	0.93255289	0.3420909	Up
GAD1	Brown	0.73161783	0.438563072	Up
CYP4F3	Brown	0.77107806	0.332267473	Up
LOC284825	Brown	0.90421005	0.390639327	Up
AKR1B10	Brown	0.94466435	0.349974725	Up
ST3GAL4-AS1	Brown	0.82829026	0.344593738	Up
EGF	Brown	0.7182042	0.333661741	Up
UCHL1	Brown	0.88915413	0.36164859	Up
MUCL1	Brown	0.93160771	0.337691839	Up
SPP1	Brown	0.67143846	0.339937468	Up
LOC344887	Brown	0.76892349	0.309106891	Up
GPX2	Brown	0.94948456	0.366118614	Up
ALDH3A1	Brown	0.88321118	0.33550101	Up
ADH7	Brown	0.88329101	0.271419642	Up
PLA2G7	Yellow	0.66092499	0.366905932	Up
MMP12	Yellow	0.71821839	0.417223392	Up
CCL2	Yellow	0.64114665	0.356007541	Up
CLEC5A	Yellow	0.73808478	0.455162179	Up
BCL2A1	Yellow	0.88297009	0.342004632	Up
PROK2	Yellow	0.62209677	0.33735587	Up

KEGG and GO enrichment analyses

KEGG analysis (Fig. 4A-B) for 9 COPD-associated pyroptosis-related genes indicated that these genes were significantly enriched in NOD-like receptor signaling pathway (CASP4/CASP5/IL1B/AIM2), Lipid and atherosclerosis (IL1B/PLCG1/CASP6), Shigellosis (CASP4/IL1B/PLCG1), Salmonella (CASP4/CASP5/PLCG1) infection and so on (Fig. 4A). As reported, NOD-like receptor is an important family of intracellular pattern recognition receptors and the key component of the first defense against pathogen attacks, which has played a vital role in the pathogenesis and AECOPD. The results of GO analysis (Fig. 4C-D) for 9 COPD-associated pyroptosis-related genes demonstrated that these genes were involved in pyroptosis (CASP4/GZMB/AIM2/CASP6/GSDMC), activation of immune response (IL1B/AIM2/CASP6/PLCG1), regulation of inflammatory response (regulation of inflammatory response) and endopeptidase activity (CASP4/CASP5/GZMB/CASP6). The detailed results of GO analysis for 9 COPD-associated pyroptosis-related genes have revealed in Supplemental Table 4.

Moreover, we also performed KEGG analysis (Fig. 4E-F) and Go analysis (Fig. 4G-H) for 26 COPD key genes. KEGG analysis for 26 COPD key genes indicated that metabolism of xenobiotics by cytochrome P450 (CYP1B1/CYP1A1/ALDH3A1/ADH7), Chemical carcinogenesis—DNA adductsand (CYP1B1/CYP1A1/EGF) and chemical carcinogenesis—receptor activation (CYP1B1/CYP1A1/EGF) were related to COPD.

Moreover, Go analysis showed that 26 COPD key genes enriched in 299 biological processes, 17 cellular component and 55 molecular function, which indicated that these biological processes and molecular functions may contribute to the occurrence and process of COPD. The detailed results of GO analysis for 26 COPD key genes have revealed in Supplemental Table 5.

PPI analysis and gene correlation analysis

PPI analysis and gene correlation analysis were applied to explore the relationship between 9 COPD-associated pyroptosis-related genes and 26 COPD key genes. PPI analysis (Fig. 5A-B) show that these pyroptosis-related genes, especially IL1B and IL1A could interact with these COPD key genes. We also performed gene correlation analysis for 9 COPD-associated pyroptosis-related genes and 26 COPD key genes by the train set and test set. In the train set (Fig. 5C) and test set (Fig. 5D), the result showed that CASP5 and ILB exhibited a positive correlation with the expression of MMP12 and BCL2A1. Moreover, ILB also related to the expression of PLA2G7, CCL2, CLEC5A. CASP4 was positively associated with TCN1. GZMB have a positive correlation with PLA2G7. GSDMC related to CABYR negatively.

Exploration the relationship between pyroptosis-related genes and GOLD states

To evaluate whether pyroptosis-related genes has an effect on COPD progression, we also explored the relationship between 9 COPD-associated pyroptosis-related genes and GOLD states (Fig. 6). As the result, the expression of AIM2, CASP5, CHMP7 have significant differences in different GOLD states, which suggested these genes may contribute to the development of COPD.

Immune Landscape of COPD

The samples of test set were performed for the analysis of CIBERSORT. In Fig. 7A, the proportion of 22 types of immune cells in COPD patients and normal cases was shown in a violin diagram by Wilcoxon test. The distribution proportion of macrophages M0 ($p=0.0007$), macrophages M2 ($p=0.09$) and T cells follicular helper ($p=0.042$) have significant variation in COPD patients and normal cases (Figure 7B-D). Then, we evaluated the correlation between 22 types of immune cells in COPD samples (Fig. 7E). We also explored the correlation of the expression of 9 COPD-associated pyroptosis-related genes and the abundance of immune cell infiltration (Fig. 7F). As the result, the expression of GMZB was negatively associated with the abundance of Macrophages. M2. Eosinophils had a positively relation with the




Fig. 4 KEGG and GO enrichment analysis. **A-B** KEGG analysis for 9 COPD-associated pyroptosis-related genes. **C-D** Go analysis for 9 COPD-associated pyroptosis-related genes. **E-F** KEGG analysis for 26 COPD key genes. **G-H** Go analysis for 26 COPD key genes

expression of IL1B, CHMP7, CASP5, CASP4. The result suggested that the expression of 9 COPD-associated pyroptosis-related genes may influence the infiltration of these immune cells.

Discussion

In light of data suggesting that about 20% of COPD patients have experienced exacerbations per year, which resulted in significant treatment costs [30, 31]. In routine clinical work, different treatment modalities will be chosen according to disease severity from COPD [32]. However, the level of standardized treatment, pulmonary rehabilitation, and pneumococcal vaccination remain low, strengthening the work of the diagnostic and management levels is urgent [33, 34].

Pyroptosis, a form of programmed cell death and an innate immune mechanism, triggers by the activation of the ASC/caspase-1 pathway [35]. Similar to apoptosis, both would appear nuclear condensation, DNA

fragmentation and TUNEL staining [36]. However, apoptosis maintains membrane integrity, while pyroptosis would lead to pore formation and membrane rupture resulting in the release of intracellular contents and inflammatory factors [37]. Based on the current study, overactivated inflammasome in the process of pyroptosis would accelerate the progression of COPD [3].

In our research, 9 candidate genes were identified to be associated with the occurrence or development of COPD. According to the current study, the increases in reactive oxygen species (ROS) and caspase-4 have been reported to involved in induced lung cell death. Caspase-4 also highly expresses in the blood of both smokers and COPD patients up to lung cancer patients [38]. As for Caspase-5, it might be a suppressor gene of highly metastatic potential in lung cancer. GZMB levels as well as T cells expressing GZMB are increased in bronchoalveolar lavage (BAL) fluid of COPD patients. When it comes to the functions of IL-1 in lung disease,




Fig. 5 PPI analysis and gene correlation analysis. **A** The protein–protein interactions among 9 COPD-associated pyroptosis-related genes and 26 COPD key genes. **B** The rank of connection degree (number) for each gene. **C** Correlation among the expression of 9 COPD-associated pyroptosis-related genes and 26 COPD key genes in the train set. *P* values are shown as: **p* < 0.05. **D** Correlation among the expression of 9 COPD-associated pyroptosis-related genes and 26 COPD key genes in the test set. *P* values are shown as: **p* < 0.05

a study showed that IL-1 has a complex modulatory role in the development of pulmonary fibrosis, acting on structural cells by dampening collagen production and furthermore balancing the pro-fibrotic and pro-inflammatory actions of the immune system [39]. It has also been reported that NLR4 could produce IL-1R antagonist (IL-1Ra) via NF-κB, to bind IL-1β, delaying

the progression of fibrogenesis [40]. And NLR4 signaling contributes to several bacteria-induced lung inflammation, even tuberculosis [41, 42]. CASP6 were also found to be increased in the progression of fibrogenesis, but the detailed mechanism need be further explored [43]. In smoke-induced experimental COPD, AIM2 plays a vital role in regulating lung neutrophilic




Fig. 6 Exploration the relationship between pyroptosis-related genes and GOLD states. The expression of 9 COPD-associated pyroptosis-related genes in different GOLD states

inflammation and caspase-1 activation in these cells following recruitment [44]. Additionally, the activation of AIM2 inflammasome correlates with the disease severity and the protein redistribution between the nucleus and cytoplasm [45]. Research effort is currently dedicated to explore the relationship between pyroptosis-related genes and lung cancer, which concluded that overexpression of GSDMC has a predictive ability in the prognosis of lung adenocarcinoma [46]. Research effort is currently dedicated to explore the relationship between pyroptosis-related genes and lung cancer, which concluded that overexpression of GSDMC has a predictive ability in the prognosis of lung adenocarcinoma [47], and PLCG1 as a critical mediator of the FGFR1 signaling, plays a vital in regulating neuroendocrine differentiation in small cell lung cancer [48].

In our research, twenty-six COPD key genes and 9 COPD-associated pyroptosis-related genes were identified. The PPI analysis and gene correlation analysis were

applied to depict their relationship clearly. KEGG and GO analysis of COPD key genes and COPD-associated pyroptosis-related genes respectively have revealed the main mechanisms as well as pyroptosis-related mechanisms in COPD. The expression of 9 COPD-associated pyroptosis-related genes in different grade suggested that pyroptosis could contribute to the progression of COPD. The immune environment of COPD was also explored. Moreover, the relationship of pyroptosis-related genes and the expression of immune cell were also be shown in the end, which reveal that pyroptosis could influence immune microenvironment of COPD. Because pyroptosis is linked tightly to development of COPD, therefore, understanding of pyroptosis-related genes potential in treatment generated high expectations. This study may provide new insight into the novel therapeutic targets for COPD clinical treatment.

Although this particular relationship was explored to several extent, some shortcomings and limitations in




Fig. 7 Immune Landscape of COPD **A** The fraction of 22 types of immune cells in COPD patients and normal cases. **B-D** The distribution of macrophages M0, macrophages M2 and T cells follicular helper in COPD patients and normal cases. **E** The correlation of 22 types of immune cells in COPD samples. **F** The correlation of 9 COPD associated pyroptosis-related gene expression and the abundance of immune cell infiltration. P-values are shown as: *p < 0.05; **p < 0.01

our study should be recognized. First, this study used retrospective data, which may have some heterogeneity among patients. Therefore, more prospective cohort studies in larger populations are needed to test the result. Second, external validation via other clinical datasets hasn't been implemented and the biological mechanism

of some pyroptosis-related genes has not been fully elucidated. Thus, more external experiments will be conducted in further research work.

Token together, our study concluded that pyroptosis may contribute to the occurrence and development of COPD.

Conclusion

In our research, we have explored the relationship between pyroptosis-related genes and COPD key genes and the significant differential expression of COPD-associated pyroptosis-related genes in different grades to confirm that pyroptosis could contribute to the progression of COPD. The immune environment of COPD, the relationship of pyroptosis-related genes and the expression of immune cell were also be shown in the end, which reveal that pyroptosis could influence immune microenvironment of COPD. Because pyroptosis is linked tightly to the development of COPD, therefore, understanding of pyroptosis-related genes potential in treatment generated high expectations. This study may provide new insight into the novel therapeutic targets for COPD clinical treatment.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12890-023-02408-5>.

Additional file 1: Supplemental Table 1. Forty-seven pyroptosis-related.

Additional file 2: Supplemental Table 2. The clinical information of Train set samples and Test set sample.

Additional file 3: Supplemental Table 3. Nine COPD-associated pyroptosis-related genes selected by differential expression analysis.

Additional file 4: Supplemental Table 4.

Additional file 5: Supplemental Table 5.

Acknowledgements

Not applicable.

Authors' contributions

XH have contributed to the design of the study, searching the related papers and extracting data, preparing figures, analysis and interpretation of data and drafting manuscript. XL and XH took part in searching the related papers and extracting data, preparing figures, analysis and interpretation of data. FX provided the revision suggestions and participated in manuscript polishing. All authors read and approved the final submitted manuscript.

Funding

Not applicable.

Availability of data and materials

The Data used in the current study was obtained from publicly available repository. The datasets generated or analyzed during the current study are available in the GEO database (GSE5058, GSE8545, GSE11906, GSE20257 and GSE69818) repository, <https://www.ncbi.nlm.nih.gov/geo/>.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors claim no competing interests.

Received: 30 December 2022 Accepted: 31 March 2023

Published online: 17 May 2023

References

- J.L., Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. 2016. 388(10053): p. 1545–1602. [https://doi.org/10.1016/s0140-6736\(16\)31678-6](https://doi.org/10.1016/s0140-6736(16)31678-6).
- Zhong N, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. *Am J Respir Crit Care Med*. 2007;176(8):753–60. <https://doi.org/10.1164/rccm.200612-1749OC>.
- Yang X, Shan S, Du ZJ. Research progress of pyroptosis in respiratory diseases. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi*. 2020;38(11):871–4. <https://doi.org/10.3760/cma.j.cn121094-20190419-00158>.
- Pinkerton JW, et al. Inflammasomes in the lung. *Mol Immunol*. 2017;86:44–55. <https://doi.org/10.1016/j.molimm.2017.01.014>.
- Lee S, et al. Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease. *Am J Respir Cell Mol Biol*. 2016;54(2):151–60. <https://doi.org/10.1165/rcmb.2015-0231TR>.
- Yu P, et al. Pyroptosis: mechanisms and diseases. *Signal Transduct Target Ther*. 2021;6(1):128. <https://doi.org/10.1038/s41392-021-00507-5>.
- Kesavardhana S, Kanneganti TD. Mechanisms governing inflammasome activation, assembly and pyroptosis induction. *Int Immunol*. 2017;29(5):201–10. <https://doi.org/10.1093/intimm/dxx018>.
- Burdette B, et al. Gasdermin D in pyroptosis. *Acta pharmaceutica Sinica B*. 2021;11(9):2768–82. <https://doi.org/10.1016/j.apsb.2021.02.006>.
- Cheng Q, et al. Memantine ameliorates pulmonary inflammation in a mice model of COPD induced by cigarette smoke combined with LPS. *Biomed Pharmacother* =: *Biomed Pharmacother*. 2019;109:2005–13. <https://doi.org/10.1016/j.biopha.2018.11.002>.
- Barnes, P.J.T.o.a. and c. immunology, Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. 2016. 138(1): p. 16–27. doi:<https://doi.org/10.1016/j.jaci.2016.05.011>.
- Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. *European Resp J*. 2019;54(2):1900651. <https://doi.org/10.1183/13993003.00651-2019>.
- Wang CC, et al. Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendritic cell IL-1-IL-17 pathway. *J Neuroinflammation*. 2015;12:118. <https://doi.org/10.1186/s12974-015-0334-4>.
- Xiao J, et al. Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. *PLoS Biol*. 2018;16(11):e3000047. <https://doi.org/10.1371/journal.pbio.3000047>.
- Ozretić P, et al. Association of NLRP1 coding polymorphism with lung function and serum IL-1 β concentration in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). *Genes (Basel)*. 2019;10(10):783. <https://doi.org/10.3390/genes10100783>.
- Xu F, et al. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma. *Genomics*. 2020;112(6):4675–83. <https://doi.org/10.1016/j.ygeno.2020.08.014>.
- Deng M, et al. Identification of inflammation-related biomarker Lp-PLA2 for patients with COPD by comprehensive analysis. *Front Immunol*. 2021;12:670971. <https://doi.org/10.3389/fimmu.2021.670971>.
- Man SM, Kanneganti TD. Regulation of inflammasome activation. *Immunol Rev*. 2015;265(1):6–21. <https://doi.org/10.1111/immr.12296>.
- Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. *Nat Rev Cancer*. 2019;19(4):197–214. <https://doi.org/10.1038/s41568-019-0123-y>.
- Wang B, Yin Q. AIM2 inflammasome activation and regulation: A structural perspective. *J Struct Biol*. 2017;200(3):279–82. <https://doi.org/10.1016/j.jsb.2017.08.001>.
- Wei X, et al. Role of pyroptosis in inflammation and cancer. *Cell Mol Immunol*. 2022;19(9):971–92. <https://doi.org/10.1038/s41423-022-00905-x>.
- Xia X, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? *Cell Death Dis*. 2019;10(9):650. <https://doi.org/10.1038/s41419-019-1883-8>.

22. Xu F, et al. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications. *Aging (Albany NY)*. 2020;12(24):25275–93. <https://doi.org/10.18632/aging.104129>.
23. Huang X, et al. m6A RNA methylation regulators could contribute to the occurrence of chronic obstructive pulmonary disease. *J Cell Mol Med*. 2020;24(21):12706–15. <https://doi.org/10.1111/jcmm.15848>.
24. Feltrin AS, et al. Assessment of complementarity of WGCNA and NERI results for identification of modules associated to schizophrenia spectrum disorders. *PLoS One*. 2019;14(1):e0210431. <https://doi.org/10.1371/journal.pone.0210431>.
25. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res*. 2000;28(1):27–30. <https://doi.org/10.1093/nar/28.1.27>.
26. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci*. 2019;28(11):1947–51. <https://doi.org/10.1002/pro.3715>.
27. Kanehisa M, et al. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res*. 2023;51(D1):D587–d592. <https://doi.org/10.1093/nar/gkac963>.
28. Li Z, et al. Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke. *J Transl Med*. 2020;18(1):296. <https://doi.org/10.1186/s12967-020-02463-0>.
29. Gnanasekar A, et al. The intratumor microbiome predicts prognosis across gender and subtypes in papillary thyroid carcinoma. *Comput Struct Biotechnol J*. 2021;19:1986–97. <https://doi.org/10.1016/j.csbj.2021.03.032>.
30. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. *Immunol Allergy Clin North Am*. 2013;33(1):95–115. <https://doi.org/10.1016/j.jiac.2012.10.006>.
31. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. *Clin Chest Med*. 2014;35(1):157–63. <https://doi.org/10.1016/j.ccm.2013.11.001>.
32. Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. *Ann Intern Med*. 2020;173(3):itc17–itc32. <https://doi.org/10.7326/aitc202008040>.
33. Fujimoto K. Up-to-date COPD treatment. *Rinsho Byori*. 2014;62(5):471–7.
34. Roche N. Stable COPD Treatment: Where are We? *COPD*. 2018;15(2):123–9. <https://doi.org/10.1080/15412555.2018.1445214>.
35. Zhu J, Fu Y, Tu G. Role of Smad3 inhibitor and the pyroptosis pathway in spinal cord injury. *Exp Ther Med*. 2020;20(2):1675–81. <https://doi.org/10.3892/etm.2020.8832>.
36. Fan C, et al. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. *Cell Death Dis*. 2014;5(4):e1191. <https://doi.org/10.1038/cddis.2014.132>.
37. Li J, et al. Targeting TFE3 protects against lysosomal malfunction-induced pyroptosis in random skin flaps via ROS elimination. *Front Cell Dev Biol*. 2021;9:643996. <https://doi.org/10.3389/fcell.2021.643996>.
38. Colarusso C, et al. Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma. *Oncotarget*. 2021;12(11):1057–71. <https://doi.org/10.18632/oncotarget.27964>.
39. Birnhuber A, Crnkovic S. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. 2019;54(3):1900154. <https://doi.org/10.1183/13993003.00154-2019>.
40. Iannitti RG, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. *Nat Commun*. 2016;7:10791. <https://doi.org/10.1038/ncomms10791>.
41. Cai S, et al. NLR4 inflammasome-mediated production of IL-1 β modulates mucosal immunity in the lung against gram-negative bacterial infection. *J Immunol*. 2012;188(11):5623–35. <https://doi.org/10.4049/jimmunol.1200195>.
42. Ravimohan S, et al. A Common NLR4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis. *Clin Infect Dis*. 2020;71(4):924–32. <https://doi.org/10.1093/cid/ciz898>.
43. Emblom-Callahan MC, et al. Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. *Genomics*. 2010;96(3):134–45. <https://doi.org/10.1016/j.ygeno.2010.04.005>.
44. Saik O, et al. Search for New Candidate Genes Involved in the Comorbidity of Asthma and Hypertension Based on Automatic Analysis of Scientific Literature. *J Integr Bioinform*. 2018;15(4):20180054. <https://doi.org/10.1515/jib-2018-0054>.
45. Donovan C, et al. Aim2 suppresses cigarette smoke-induced neutrophil recruitment, neutrophil caspase-1 activation and anti-Ly6G-mediated neutrophil depletion. *Immunol Cell Biol*. 2022. <https://doi.org/10.1111/imcb.12537>.
46. Tran HB, et al. AIM2 nuclear exit and inflammasome activation in chronic obstructive pulmonary disease and response to cigarette smoke. *J Inflamm (Lond)*. 2021;18(1):19. <https://doi.org/10.1186/s12950-021-00286-4>.
47. Wei J, et al. Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma. *Mol Med Rep*. 2020;21(1):360–70. <https://doi.org/10.3892/mmr.2019.10837>.
48. Kim KB, et al. FGFR1 Is critical for RBL2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer. *Cancer Res*. 2020;80(22):5051–62. <https://doi.org/10.1158/0008-5472.Can-20-1453>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

